drugset / Trial / NCT02955693

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008

NCT02955693

Phase 1 Completed 32 enrolled Almirall, S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate \[DMF\]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant tablet under fasting and fed conditions. The study also aims to assess the safety of the study treatments.

Timeline

Start
2016-09
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fumaric acid Small molecule 120 mg
Subject dimethyl fumarate Unknown 120 mg

Indications